{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:26:05Z","timestamp":1788837965480,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s10067-011-1877-0","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T04:34:19Z","timestamp":1320726859000},"page":"13-21","source":"Crossref","is-referenced-by-count":38,"title":["An update on the pathology and clinical management of gouty arthritis"],"prefix":"10.1007","volume":"31","author":[{"given":"Emilio B.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,9]]},"reference":[{"issue":"1","key":"1877_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","volume":"40","author":"HM Kramer","year":"2002","unstructured":"Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988\u20131994. Am J Kidney Dis 40(1):37\u201342","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1877_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26\u201335","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1877_CR3","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10\u00a0years among older adults in a managed care population. J Rheumatol 31(8):1582\u20131587","journal-title":"J Rheumatol"},{"issue":"6","key":"1877_CR4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","volume":"10","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Wallace K et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308\u2013314","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"1877_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143(7):499\u2013516","journal-title":"Ann Intern Med"},{"issue":"6 Suppl","key":"1877_CR6","first-page":"S1","volume":"59","author":"MA Becker","year":"2010","unstructured":"Becker MA, Ruoff GE (2010) What do I need to know about gout? J Fam Pract 59(6 Suppl):S1\u2013S8","journal-title":"J Fam Pract"},{"issue":"6957","key":"1877_CR7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01991","volume":"425","author":"Y Shi","year":"2003","unstructured":"Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516\u2013521","journal-title":"Nature"},{"issue":"7081","key":"1877_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237\u2013241","journal-title":"Nature"},{"issue":"11","key":"1877_CR9","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","volume":"62","author":"LA Joosten","year":"2010","unstructured":"Joosten LA, Netea MG, Mylona E et al (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 62(11):3237\u20133248","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1877_CR10","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","volume":"56","author":"RM Pope","year":"2007","unstructured":"Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183\u20133188","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1877_CR11","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2009.109355","volume":"68","author":"R Torres","year":"2009","unstructured":"Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68(10):1602\u20131608","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1877_CR12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/ard.2010.128454","volume":"69","author":"N Schlesinger","year":"2010","unstructured":"Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69(11):1907\u20131912","journal-title":"Ann Rheum Dis"},{"issue":"28","key":"1877_CR13","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.1073\/pnas.0610812104","volume":"104","author":"J Zwerina","year":"2007","unstructured":"Zwerina J, Redlich K, Polzer K et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104(28):11742\u201311747","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1877_CR14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312\u20131324","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1877_CR15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060\u20131068","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1877_CR16","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46(8):1372\u20131374","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1877_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O'Brien WR, Lee KH et al (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124(2):155\u2013163","journal-title":"Am J Med"},{"issue":"3","key":"1877_CR18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","volume":"40","author":"K Chen","year":"2010","unstructured":"Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L (2010) Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 40(3):210\u2013214","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1877_CR19","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"1877_CR20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR et al (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68(10):1613\u20131617","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1877_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","volume":"2","author":"E Dhimolea","year":"2010","unstructured":"Dhimolea E (2010) Canakinumab. MAbs 2(1):3\u201313","journal-title":"MAbs"},{"issue":"10","key":"1877_CR22","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De MM, Pikhlak A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064\u20133076","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1877_CR23","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De MM, Pikhlak A et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1877_CR24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25\u201332","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1877_CR25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093\u20131103","journal-title":"N Engl J Med"},{"issue":"9417","key":"1877_CR26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","volume":"363","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363(9417):1277\u20131281","journal-title":"Lancet"},{"issue":"3","key":"1877_CR27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52(3):916\u2013923","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1877_CR28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548","journal-title":"Arthritis Rheum"},{"issue":"23","key":"1877_CR29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461","journal-title":"N Engl J Med"},{"issue":"2","key":"1877_CR30","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1877_CR31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker MA, Macdonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27(6):585\u2013591","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"14","key":"1877_CR32","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann RL, Macdonald PA, Hunt B, Jackson RL (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386\u20132397","journal-title":"Clin Ther"},{"issue":"32","key":"1877_CR33","doi-asserted-by":"crossref","first-page":"14351","DOI":"10.1073\/pnas.1001072107","volume":"107","author":"MS Hershfield","year":"2010","unstructured":"Hershfield MS, Roberts LJ, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107(32):14351\u201314356","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1877_CR34","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","volume":"58","author":"JS Sundy","year":"2008","unstructured":"Sundy JS, Becker MA, Baraf HSB et al (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 58(9):2882\u20132891","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1877_CR35","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/art.23993","volume":"58","author":"HBB Baraf","year":"2008","unstructured":"Baraf HBB, Matsumoto AK, Maroli AM, Waltrip RW (2008) Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 58(11):3632\u20133634","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1877_CR36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7):711\u2013720","journal-title":"JAMA"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10067-011-1877-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T09:18:08Z","timestamp":1497950288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-011-1877-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1877"],"URL":"https:\/\/doi.org\/10.1007\/s10067-011-1877-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,9]]}}}